Previously, in patients with ALK-positive non-small-cell lung cancer, treatment with chemotherapy or crizotinib was recommended. However, crizotinib showed an objective response rate of 74%, ceritinib with 63.7%, and alectinib with 93.5%. Based on this, alectinib is effective in treating these patients. Here, ALK is linked to non-small cell lung carcinoma.